Epigenetic Therapy in Malignant and Chronic DiseasesHussein Chahin, Bassey Ekong and Tamer E Fandy *
Department of Pharmaceutical Sciences, Albany College of Pharmacy, Colchester, VT 05446, USA
- *Corresponding Author:
- Tamer E Fandy
Department of Pharmaceutical Sciences
Albany College of Pharmacy
261 Mountain View Dr
Colchester, VT 05446, USA
E-mail: [email protected]
Received date: June 25, 2013; Accepted date: July 20, 2013; Published date: July 27, 2013
Citation: Chahin H, Ekong B, Fandy TE (2013) Epigenetic Therapy in Malignant and Chronic Diseases. J Pharmacogenom Pharmacoproteomics 4:118. doi: 10.4172/2153-0645.1000118
Copyright: © 2013 Chahin H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The role of epigenetics in cancer development establishes enzymes that regulate epigenetic modifications as vital targets for cancer therapy. Inhibition of DNA Methyltransferase (DNMT) and Histone Deacetylase (HDAC) enzymes proved to be a successful strategy in the treatment of some types of cancer. There is currently growing interest in studying the effect of inhibition of enzymes affecting other histone modifications, like histone methylation, and how they can affect cancer development and progression. A major limitation of epigenetic therapy is the lack of specificity with consequent global induction of epigenetic changes. Additionally, optimal dosing, single or combined therapy and the sequence of delivery of combined therapy are clinical issues associated with the use of these drugs. Herein, we will summarize the impact of using the different classes of epigenetic drugs in cancer and other chronic diseases.